Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2003	HAYES, Inc.	Ventricular reduction surgery
1997	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Ventricular assistance devices as mechanical bridge to cardiac transplantation (internal report) IPE-97/f
2010	HAYES, Inc.	Ventricular Assist Devices (VADs) in children and adolescents with chronic, end-stage heart failure
2005	HAYES, Inc.	Ventricular assist devices
2003	HAYES, Inc.	Ventricular assist devices
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Ventral rectopexy for the treatment of rectal prolapse and intussusception
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ventilation/perfusion scintigraphy (using Technegas) versus computed tomography pulmonary angiography for the diagnosis of pulmonary embolism in hospitalized patients: a review of the clinical and cost-effectiveness
2013	New Zealand National Health Committee (NHC)	Ventilation tubes: an opportunity for better targeting - technology note
2001	Norwegian Knowledge Centre for the Health Services (NOKC)	Ventilation in operating theatres
2012	Agency for Healthcare Research and Quality (AHRQ)	Venous thromboembolism prophylaxis in orthopedic surgery
2007	Penn Medicine Center for Evidence-based Practice (CEP)	Venous thromboembolism prophylaxis for medical inpatients
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines
2007	Penn Medicine Center for Evidence-based Practice (CEP)	Venous thromboembolism prophylaxis for ischemic stroke
2007	Penn Medicine Center for Evidence-based Practice (CEP)	Venous thromboembolism prophylaxis for hip fracture patients
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Venous thromboembolism prophylaxis for bariatric surgery
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Venous Thromboembolism Prevention for Obese Patients
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Venous irritation resulting from IV fosaprepitant
2021	NIHR Health Technology Assessment programme	Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Venetoclax with rituximab for relapsed or refractory chronic lymphocytic leukaemia – second and subsequent line
2019	National Institute for Health and Care Excellence (NICE)	Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2020	National Institute for Health and Care Excellence (NICE)	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 765
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Venetoclax for chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion
2012	National Institute for Health and Care Excellence (NICE)	Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269
2012	NIHR Health Technology Assessment programme	Vemurafenib for the treatment of locally advanced or metastatic BRAF V600E mutation positive malignant melanoma
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Vemurafenib and cobimetinib for previously untreated BRAFV600-mutation positive, unresectable, locally advanced or metastatic melanoma – first line
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Vemurafenib (Zelboraf) for metastatic BRAF V600 mutation positive melanoma in children and adolescents
2008	Adelaide Health Technology Assessment (AHTA)	Velscope(R) for oral cancer screening
2010	Adelaide Health Technology Assessment (AHTA)	Velscope for oral cancer screening
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Velimogene aliplasmid (Allovectin) for advanced or metastatic malignant melanoma
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Velcalcetide for secondary hyperparathyroidism – first line
2010	HAYES, Inc.	Velcade (Bortezomib) (Millennium: The Takeda Oncology Company) for mantle cell lymphoma
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Velaglucerase alfa for type 1 Gaucher's disease
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Velaglucerase alfa
2012	HAYES, Inc.	VeinViewer (Christie Digital Systems USA Inc.) for guiding venous access procedures in children
1998	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Vein-graft surveillance - primary research
2024	NIHR Health Technology Assessment programme	Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2011	NIHR Horizon Scanning Centre (NIHR HSC)	VEGF trap-eye (Eylea) for macular oedema secondary to central retinal vein occlusion - first line
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Vedolizumab for ulcerative colitis – second or subsequent line
2019	Agency for Care Effectiveness (ACE)	Vedolizumab for treating ulcerative colitis and Crohn's disease
2015	National Institute for Health and Care Excellence (NICE)	Vedolizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 342
2015	National Institute for Health and Care Excellence (NICE)	Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. NICE technology appraisal guidance 352
2014	NIHR Health Technology Assessment programme	Vedolizumab for treating moderate to severe active Crohn's disease after prior therapy [ID690]
2022	National Institute for Health and Care Excellence (NICE)	Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Vedolizumab for Crohn's disease – second or subsequent line
2022	Scottish Health Technologies Group (SHTG)	vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2012	NIHR Horizon Scanning Centre (NIHR HSC)	VBLOC® vagal blocking therapy for obesity
2009	HAYES, Inc.	VasoView HemoPro endoscopic vein harvesting system (Maquet Cardiovascular LLC) for coronary artery bypass graft (CABG)
2005	Adelaide Health Technology Assessment (AHTA)	Vasotrac (R) continuous blood pressure monitoring
2003	Centre for Clinical Effectiveness (CCE)	Vasospasm following subarachnoid haemorrhage: papaverine infusion, nimodipine infusion or balloon angioplasty?
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vasoprotectives: efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vasopressin as first-line therapy for cardiac arrest: a review of the guidelines and clinical-effectiveness
2015	Health Quality Ontario (HQO)	Vasodilators for inhospital heart failure management: a rapid review (update)
2013	Health Quality Ontario (HQO)	Vasodilators for inhospital heart failure management: a rapid review
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
1989	The Swedish Council on Health Technology Assessment (SBU)	Vascular surgery for arteriosclerosis in the legs
2007	Institute for Clinical Effectiveness and Health Policy (IECS)	Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2007	Institute for Clinical Effectiveness and Health Policy (IECS)	Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2004	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Vascular bipolar electrocoagulation (LigaSure (TM)) and Tissular electrocoagulation and section (TissueLink (TM)) - preliminary report
2000	University HealthSystem Consortium (UHC)	Varicella-zoster
2014	New Zealand National Health Committee (NHC)	Varicella and rotovirus vaccination in New Zealand - assessment reports
2020	NIHR Health Services and Delivery Research programme	Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
1993	Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS)	Variations in the frequency of surgical procedures by region in the province of Quebec - nonsystematic review
1996	Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS)	Variations in rates of tonsillectomy, adenoidectomy and myringotomy in Quebec - nonsystematic review
2014	NIHR Health Services and Delivery Research programme	Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data
2017	NIHR Health Services and Delivery Research programme	Variations in mortality across the week following emergency admission to hospital: linked retrospective observational analyses of hospital episode data in England, 2004/5 to 2013/14
2014	NIHR Health Services and Delivery Research programme	Variation in compulsory psychiatric inpatient admission in England: a cross-sectional, multilevel analysis
2001	Health Council of the Netherlands Gezondheidsraad (GR)	Variant Creutzfeldt-Jakob disease and blood transfusion - review, expert panel
2009	NIHR Health Technology Assessment programme	Varenicline in the management of smoking cessation: a single technology appraisal
2007	National Institute for Health and Care Excellence (NICE)	Varenicline for smoking cessation. NICE technology appraisal guidance 123
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Varenicline for smoking cessation in patients with psychiatric illness: a review of the risks
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Varenicline for smoking cessation
2007	Quality Improvement Scotland (NHS QIS )	Varenicline for smoking cessation
2018	National Institute for Health and Care Excellence (NICE)	Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Vandetanib (Zactima, -6474, AZD-6474, ZD6474) for medullary thyroid cancer – locally advanced or metastatic
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vancomycin or metronidazole for treatment of clostridium difficile infection: clinical and economic analyses
2025	National Institute for Health and Care Excellence (NICE)	Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over. NICE technology appraisal guidance 1031
2019	National Institute for Health and Care Excellence (NICE)	Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction. NICE interventional procedures guidance 653
2011	Agency for Healthcare Research and Quality (AHRQ)	Values of older adults related to primary and secondary prevention
2006	Agency for Healthcare Research and Quality (AHRQ)	Value of the periodic health evaluation
2007	Haute Autorite de sante (HAS)	Value of mutation detection and of the activated protein C resistance assay in inherited thrombophilia
2005	Haute Autorite de sante (HAS)	Value of measuring FSH and LH levels in women aged 45 or over
2007	Haute Autorite de sante (HAS)	Value of mandibular advancement devices in cases of obstructive sleep apnea-syndrome
1999	Hannover Medical School, Medizinische Hochschule Hannover (MHH)	Value of intravascular ultrasound (IVUS) in diagnostic and therapeutic heart catherisation in patients with coronary heart disease - an economic health technology assessment
2007	Haute Autorite de sante (HAS)	Value of intensity-modulated radiation therapy
2006	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	Value of intensified nursing
2007	Haute Autorite de sante (HAS)	Value of extra-cranial stereotactic radiotherapy
1994	L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES)	Value of echoendoscopy in gastrointestinal disease
2014	University of York	Value based commissioning of MSK Procedures: an appraisal of the evidence for the proposed policies
2023	Institute for Clinical and Economic Review (ICER)	Value assessment framework
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valsartan (Diovan®)
2020	Institute for Clinical and Economic Review (ICER)	Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value